-transparent.png){kind=logo}
Coagulation factors, including plasma fibrinogen, serum fibrinogen-fibrin degradation products, platelet counts and prothrombin times, were studied in patients with renal adenocarcinoma. Plasma fibrinogen levels were elevated and correlated with tumor stage, disease activity and therapy. Fibrinogen-fibrin degradation product levels also were elevated, although such elevations did not correlate with other parameters. Platelet count and prothrombin times were normal. Fibrinogen may be a valuable marker of disease activity in patients with renal carcinoma. In addition, since significant intratumoral fibrin deposits have been demonstrated anticoagulants or fibrinolytic agents may enhance cytotoxic therapy and should be considered in adjunctive chemotherapeutic protocols.
G Sufrin, and
I Mink, and
J Fitzpatrick, and
R Moore, and
G P Murphy
January 1988,
Progress in clinical and biological research,
G Sufrin, and
I Mink, and
J Fitzpatrick, and
R Moore, and
G P Murphy
November 2003,
Archivos espanoles de urologia,
G Sufrin, and
I Mink, and
J Fitzpatrick, and
R Moore, and
G P Murphy
June 1987,
Seminars in nephrology,
G Sufrin, and
I Mink, and
J Fitzpatrick, and
R Moore, and
G P Murphy
April 1950,
Klinische Wochenschrift,
G Sufrin, and
I Mink, and
J Fitzpatrick, and
R Moore, and
G P Murphy
November 1947,
Lancet (London, England),
G Sufrin, and
I Mink, and
J Fitzpatrick, and
R Moore, and
G P Murphy
November 1947,
Lancet (London, England),
G Sufrin, and
I Mink, and
J Fitzpatrick, and
R Moore, and
G P Murphy
January 1953,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
G Sufrin, and
I Mink, and
J Fitzpatrick, and
R Moore, and
G P Murphy
January 1967,
Annali di medicina navale,
G Sufrin, and
I Mink, and
J Fitzpatrick, and
R Moore, and
G P Murphy
April 1961,
Jibi inkoka Otolaryngology,
G Sufrin, and
I Mink, and
J Fitzpatrick, and
R Moore, and
G P Murphy
December 1947,
Lancet (London, England),
